2025-04-08 18:34:20
Latest Post
Godrej Properties delivers its highest ever quarterly and full year bookings
Poonawalla Fincorp Launches Shopkeeper Loan Business
Revolt Motors Expands to 200 Dealerships, Targets 400 by FY26
Sobha Ltd - Real Estate Operational Update - Q4 FY 2024-25
Lemon Tree Hotels signs a new property in DarjeelingStock Report
Suven Pharmaceuticals Ltd Q2FY21 consolidated PAT slips to Rs. 74.07 crore
Posted On : 2020-10-30 14:35:10( TIMEZONE : IST )
Suven Pharmaceuticals Ltd. has reported financial results for the period ended September 30, 2020.
Financial Results (Q2 FY20-21) - QoQ Comparison
The company has reported total income of Rs.237.74 crores during the period ended September 30, 2020 as compared to Rs.243.97 crores during the period ended June 30, 2020.
The company has posted net profit / (loss) of Rs.74.07 crores for the period ended September 30, 2020 as against net profit / (loss) of Rs.91.52 crores for the period ended June 30, 2020.
The company has reported EPS of Rs.2.91 for the period ended September 30, 2020 as compared to Rs.3.60 for the period ended June 30, 2020.
| Financials | Q2 FY20-21 | Q1 FY20-21 | % Change |
| Total Income | ₹ 237.74 crs | ₹ 243.97 crs |  -2.55% |
| Net Profit | ₹ 74.07 crs | ₹ 91.52 crs | -19.07% |
| EPS | ₹ 2.91 | ₹ 3.60 | -19.17% |
Financial Results (Q2 FY20-21) - YoY Comparison
The company has reported total income of Rs.237.74 crores during the period ended September 30, 2020 as compared to Rs.278.37 crores during the period ended September 30, 2019.
The company has posted net profit / (loss) of Rs.74.07 crores for the period ended September 30, 2020 as against net profit / (loss) of Rs.93 crores for the period ended September 30, 2019.
The company has reported EPS of Rs.2.91 for the period ended September 30, 2020 as compared to Rs.3.65 for the period ended September 30, 2019.
| Financials | Q2 FY20-21 | Q2 FY19-20 | % Change |
| Total Income | ₹ 237.74 crs | ₹ 278.37 crs | -14.6% |
| Net Profit | ₹ 74.07 crs | ₹ 93 crs | -20.35% |
| EPS | ₹ 2.91 | ₹ 3.65 | -20.27% |
Financial Results (6 months ended FY 20-21) - YoY Comparison
The company has reported total income of Rs.481.71 crores during the 6 months period ended September 30, 2020 as compared to Rs.478.20 crores during the 6 months period ended September 30, 2019.
The company has posted net profit / (loss) of Rs.165.60 crores for the 6 months period ended September 30, 2020 as against net profit / (loss) of Rs.184.90 crores for the 6 months period ended September 30, 2019.
The company has reported EPS of Rs.6.51 for the 6 months period ended September 30, 2020 as compared to Rs.7.26 for the 6 months period ended September 30, 2019.
| Financials | Half-Year Ended FY20-21 | Half-Year Ended FY19-20 | % Change |
| Total Income | ₹ 481.71 crs | ₹ 478.20 crs |  0.73% |
| Net Profit | ₹ 165.60 crs | ₹ 184.90 crs | -10.44% |
| EPS | ₹ 6.51 | ₹7.26 | -10.33% |
Shares of Suven Pharmaceuticals Ltd. was last trading in BSE at Rs. 303.20 as compared to the previous close of Rs. 338.70. The total number of shares traded during the day was 0.46 lakh shares at an average price of Rs. 305.77.
The stock hit an intraday high of Rs. 341.45 and intraday low of Rs. 292.
